This small-cap ASX healthcare stock just exploded 131%! Here's why

Investors are sending the ASX small-cap healthcare stock soaring on Tuesday.

Investors in ASX small-cap stock Invion Ltd (ASX: IVX) could have doubled their money today.

All in a few hours' time.

Shares in the ASX healthcare company closed yesterday trading for 18 cents. In earlier trade, shares were trading for 41.5 cents apiece, up an eye-popping 130.6%. After some likely profit-taking, at the time of writing, shares are changing hands for 36 cents each, up 100.0%.

For some context, the All Ordinaries Index (ASX: XAO) is up 0.6% at this same time.

Here's what's sending the ASX small-cap stock through the roof today.

Doctor doing a telemedicine using laptop at a medical clinic

Image source: Getty Images

ASX small-cap rockets on cancer trial progress

The Invion share price is rocketing after the ASX small-cap stock reported that the first patient has been dosed in its Phase I/II non-melanoma skin cancer (NMSC) trial, which is being conducted at Veracity Clinical Research in Brisbane.

The trial is intended to evaluate the safety and efficacy of Invion's lead drug candidate, INV043, for the treatment of multiple cancers. INV043 is a novel photosensitiser developed in Australia for use in Photodynamic Therapy (PDT).

Likely helping spur interest in the ASX small-cap stock today, the company noted that skin cancer is one of the world's most common cancers. NMSC makes up over 98% of all skin cancers, with the global treatment market forecast to hit US$21.1 billion by 2032.

Invion said that the study initially aims to assess the safety profile of the topically applied INV043 in non-metastatic cutaneous Squamous Cell Carcinoma (cSCC). Subsequent parts are intended to address dose optimisation and the identification of efficacy signals.

Part 3 of the trial will expand testing to include superficial Basal Cell Carcinoma (sBCC).

The trial will enrol a minimum of 18 patients, which Invion said can be increased depending on the results.

What did management say?

Commenting on the trial progress sending the ASX small-cap stock flying higher today, Invion CEO Thian Chew said, "Having the first patient dosed in our NMSC trial is a significant milestone for Invion in demonstrating the potential for the Photosoft technology to address limitations and undesirable side effects of current standard of care for NMSCs, including scarring and pain."

Chew added:

On the back of the recently announced prostate cancer results, this trial can also provide clinical evidence that INV043 can be safely used in more than one formulation to treat multiple cancers. This can then open up the potential for our next-generation PDT to become an important alternative modality for treating cancers.

Foolish takeaway

Like most ASX small-cap stocks, Invion's share price can see some big daily swings, both higher and lower. If you're investing in the small end of the market, be prepared to weather some volatility.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

An ASX investor relaxes on her couch as the Harvey Norman share price drops due to the shares trading ex-dividend from today.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX managed to pull a rabbit out of the hat today.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough session for the ASX this Thursday.

Read more »

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

It was a volatile, but successful, day for investors.

Read more »

Three men stand on a winner's podium with medals around their necks and their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a muted day on the ASX.

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy start to the trading week this Monday.

Read more »

Girl with painted hands.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a remarkably positive end to the trading week.

Read more »

3 children standing on podiums wearing Olympic medals.
Share Gainers

Here are the top 10 ASX 200 shares today

A late rally couldn't save the ASX this Thursday.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rather woeful Wednesday for the markets.

Read more »